CDK8-IN-19

• Target:

  PI3K|||CDK

• Related Pathways:

  PI3K/Akt/mTOR signaling|||Cell Cycle/Checkpoint

• Bioactivity:

  CDK8-IN-19 (Compound 3d) is a CDK8 inhibitor with an IC50 of 25.08 nM. It exhibits broad-spectrum anticancer activity, showing effectiveness against leukemia, melanoma, and breast cancer, while demonstrating no significant cytotoxicity to normal Vero cells (mean IC50 values are 2.87, 3.65, 3.79, and 45.48 ?M, respectively) .

• Shipping Conditions:

  Cool pack

• Storage Temperature:

  -20°C